STOCK MARKET BSE NSE

COVID vaccine from any country will work in India: Hyderabad-based research centre

The reason behind this is that the strain of the novel Coronavirus widely prevalent in India is the same as the one in most parts of the world - i.e., it belongs to the A2a clade.

Published: 20th September 2020 01:21 AM  |   Last Updated: 20th September 2020 09:38 AM   |  A+A-

coronavirus, PPE, COVID 19

For representational purposes (Photo | PTI)

Express News Service

HYDERABAD: As the world races to discover a vaccine against COVID-19, a piece of good news that has emerged from Hyderabad-based Centre for Cellular and Molecular Biology (CCMB) is that a vaccine developed in any part of the world can prove equally useful in India. 

The reason behind this is that the strain of the novel Coronavirus widely prevalent in India is the same as the one in most parts of the world — i.e., it belongs to the A2a clade — CCMB researchers have found. 
The researchers report that the localised mutant strain of the virus discovered in India in the initial months of the pandemic, the A3i clade, is becoming less and less prevalent — from 40 per cent a few months ago to 18 per cent now.

It is mostly limited to Delhi. This is expected to decrease further. The analysis was published in the Open Forum For Infectious Diseases (OFID) by Oxford Academic under the title - 'A distinct phylogenetic cluster of Indian SARS-CoV-2 isolates'. 

As the virus strain in India belongs to the globally prevalent A2a clade, which is known for high infectivity but not severity or death, it is being looked at as good news because world over vaccine development is happening to counter this particular strain of the virus. This means that if any country successfully comes out with a vaccine, it will be of use in India as well.   

Virus is not mutating fast, says CCMB

CCMB scientist Divya Tej Sowpati tweeted a thread on Saturday on this topic, in which he said, “If a vaccine/drug targeting this mutation (A2a) is developed anywhere in the world, it will work with the same efficiency even here (India)”.

CCMB Director Dr Rakesh Mishra explained that the benefits of a common virus strain world over is not only in terms of better success of a drug or vaccine, but also shows that the virus is not mutating quickly. Moreover, nothing significant has been seen to suggest that the virus could become more aggressive or infectious and that it is mutating at an expected rate, he said.



Comments(1)

Disclaimer : We respect your thoughts and views! But we need to be judicious while moderating your comments. All the comments will be moderated by the newindianexpress.com editorial. Abstain from posting comments that are obscene, defamatory or inflammatory, and do not indulge in personal attacks. Try to avoid outside hyperlinks inside the comment. Help us delete comments that do not follow these guidelines.

The views expressed in comments published on newindianexpress.com are those of the comment writers alone. They do not represent the views or opinions of newindianexpress.com or its staff, nor do they represent the views or opinions of The New Indian Express Group, or any entity of, or affiliated with, The New Indian Express Group. newindianexpress.com reserves the right to take any or all comments down at any time.

  • Yash Pal

    Goo news as far as a vaccine for covid 19 is concerned.
    2 months ago reply
IPL_2020
flipboard facebook twitter whatsapp